69 research outputs found
Castor Leaves-Based Biochar for Adsorption of Safranin from Textile Wastewater
The prospect of synthesizing biochar from agricultural wastes or by-products to utilize them as a promising adsorbent material is increasingly gaining attention. This research work focuses on synthesizing biochar from castor biomass (CBM) and evaluating its potential as an adsorbent material. Castor biomass-based biochar (CBCs) prepared by the slow pyrolysis process at different temperatures (CBC400 °C, CBC500 °C, and CBC600 °C for 1 h) was investigated for the adsorption of textile dye effluents (safranin). The pyrolysis temperature played a key role in enhancing the morphology, and the crystallinity of the biochar which are beneficial for the uptake of safranin. The CBC600 adsorbent showed a higher safranin dye removal (99.60%) and adsorption capacity (4.98 mg/g) than CBC500 (90.50% and 4.52 mg/g), CBC400 (83.90% and 4.20 mg/g), and castor biomass (CBM) (64.40% and 3.22 mg/g). Adsorption data fitted better to the Langmuir isotherm model than to the Freundlich isotherm model. The kinetics of the adsorption process was described well using the pseudo-second-order kinetic model. The study on the effect of the contact time for the adsorption process indicated that for CBC600, 80% dye removal occurred in the first 15 min of the contact time. After three regeneration cycles, CBC600 exhibited the highest dye removal efficiency (64.10%), highlighting the enhanced reusability of CBCs. The crystalline patterns, functional binding sites, and surface areas of the prepared CBCs (CBC400, CBC500, CBC600) were characterized by X-ray diffraction, Fourier transform infrared spectroscopy, and Brunauer–Emmett–Teller surface area measurements, respectively
Edoxaban: an update on the new oral direct factor Xa inhibitor.
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with non-valvular atrial fibrillation (NVAF) and symptomatic venous thromboembolism (VTE). The ENGAGE AF-TIMI 48 study (NÂ =Â 21,105; mean CHADS2 score 2.8) compared edoxaban 60Â mg once daily (high-dose regimen) and edoxaban 30Â mg once daily (low-dose regimen) with dose-adjusted warfarin [international normalized ratio (INR) 2.0-3.0] and found that both regimens were non-inferior to warfarin in the prevention of stroke and systemic embolism in patients with NVAF. Both edoxaban regimens also provided significant reductions in the risk of hemorrhagic stroke, cardiovascular mortality, major bleeding and intracranial bleeding. The Hokusai-VTE study (NÂ =Â 8,292) in patients with symptomatic VTE had a flexible treatment duration of 3-12Â months and found that following initial heparin, edoxaban 60Â mg once daily was non-inferior to dose-adjusted warfarin (INR 2.0-3.0) for the prevention of recurrent VTE, and also had a significantly lower risk of bleeding events. Both studies randomized patients at moderate-to-high risk of thromboembolic events and were further designed to simulate routine clinical practice as much as possible, with edoxaban dose reduction (halving dose) at randomisation or during the study if required, a frequently monitored and well-controlled warfarin group, a well-monitored transition period at study end and a flexible treatment duration in Hokusai-VTE. Given the phase III results obtained, once-daily edoxaban may soon be a key addition to the range of antithrombotic treatment options
Assessment of endogenous fibrinolysis in clinical using novel tests - Ready for clinical roll-out?
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The occurrence of thrombotic complications, which can result in excess mortality and morbidity, represent an imbalance between the pro-thrombotic and fibrinolytic equilibrium.The mainstay treatment of these complications involves the use of antithrombotic agents but despite advances in pharmacotherapy, there remains a significant proportion of patients who continue to remain at risk.Endogenous fibrinolysis is a physiological counter-measure against lasting thrombosis and may be measured using several techniques to identify higher risk patients who may benefit from more aggressive pharmacotherapy. However, the assessment of the fibrinolytic systemis not yet accepted into routine clinical practice.In this review, we will revisit the different methods of assessing endogenous fibrinolysis (factorial assays, turbidimetric lysis assays, viscoelastic and the global thrombosis tests), including the strengths, limitations, correlation to clinical outcomes of each method and howwe might integrate the assessment of endogenous fibrinolysis into clinical practice in the future.Peer reviewedFinal Published versio
Search for a light exotic particle in J/psi radiative decays
Using a data sample containing 1.06x10^8 psi' events collected with the
BESIII detector at the BEPCII electron-positron collider, we search for a light
exotic particle X in the process psi' -> pi^+ pi^- J/psi, J/psi -> gamma X, X
-> mu^+ mu^-. This light particle X could be a Higgs-like boson A^0, a spin-1 U
boson, or a pseudoscalar sgoldstino particle. In this analysis, we find no
evidence for any mu^+mu^- mass peak between the mass threshold and 3.0 GeV/c^2.
We set 90%-confidence-level upper limits on the product-branching fractions for
J/psi -> gamma A^0, A^0 -> mu^+ mu^- which range from 4x10^{-7} to 2.1x10^{-5},
depending on the mass of A^0, for M(A^0)<3.0 GeV/c^2. Only one event is seen in
the mass region below 255 MeV/c^2 and this has a mu^+mu^- mass of 213.3 MeV/c^2
and the product branching fraction upper limit 5x10^{-7}.Comment: 7 pages, 3 figures, submitted to Physical Review
Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study
Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.
Photovoltaic Panels Classification Using Isolated and Transfer Learned Deep Neural Models Using Infrared Thermographic Images
Defective PV panels reduce the efficiency of the whole PV string, causing loss of investment by decreasing its efficiency and lifetime. In this study, firstly, an isolated convolution neural model (ICNM) was prepared from scratch to classify the infrared images of PV panels based on their health, i.e., healthy, hotspot, and faulty. The ICNM occupies the least memory, and it also has the simplest architecture, lowest execution time, and an accuracy of 96% compared to transfer learned pre-trained ShuffleNet, GoogleNet, and SqueezeNet models. Afterward, ICNM, based on its advantages, is reused through transfer learning to classify the defects of PV panels into five classes, i.e., bird drop, single, patchwork, horizontally aligned string, and block with 97.62% testing accuracy. This proposed approach can identify and classify the PV panels based on their health and defects faster with high accuracy and occupies the least amount of the system’s memory, resulting in savings in the PV investment
Karakorum temperature out of phase with hemispheric trends for the past five centuries
Climate Dynamics, doi:10.1007/s00382-015-2685-
Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure
- …